Atherosclerosis arises from leukocyte infiltration and thickening of the artery walls and constitutes a major component of vascular disease pathology, but the molecular events underpinning this process are not fully understood. Proteins containing an Asn-Gly-Arg (NGR) motif readily undergo deamidation of asparagine to generate isoDGR structures that bind to integrin α v β 3 on circulating leukocytes. Here we report the identification of isoDGR motifs in human atherosclerotic plaque components including extracellular matrix (ECM) proteins fibronectin and tenascin C, which have been strongly implicated in human atherosclerosis. We further demonstrate that deamidation of NGR motifs in fibronectin and tenascin C leads to increased adhesion of the monocytic cell line U937 and enhanced binding of primary human monocytes, except in the presence of a α v β 3 -blocking antibody or the α v -selective inhibitor cilengitide. In contrast, under the same deamidating conditions monocyte-macrophages displayed only weak binding to the alternative ECM component vitronectin which lacks NGR motifs. Together, these findings confirm a critical role for isoDGR motifs in mediating leukocyte adhesion to the ECM via integrin α v β 3 and suggest that protein deamidation may promote the pathological progression of human atherosclerosis by enhancing monocyte recruitment to developing plaques.
acid isoforms from a succinimide intermediary 20, 21 . Blast analyses indicate that ~5% of all proteins contain at least one NGR sequence and that ~0.5% contain several of these motifs. However, not all NGR sites are equally susceptible to deamidation, and subsequent changes in protein function also depend on amino acid sequence, molecular structure, and microenvironmental conditions 22 . Indeed, while the majority of previous studies have reported that deamidation inhibits protein function 23 , in certain settings this modification may instead confer gain-of-function changes that mediate key pathological events in age-related human diseases.
Inflammatory processes such as atherosclerosis induce protein oxidation, which leads to structural changes that promote NGR deamidation 22, 24 . Rather than disrupting immune responses, deamidation of NGR has previously been identified as a gain-of-function change that generates an integrin-binding isoAsp-Gly-Arg (isoDGR) structure which mimics the cognate Arg-Gly-Asp (RGD) target sequence 21, [25] [26] [27] [28] [29] [30] [31] [32] . Integrin-mediated adhesion of circulating monocytes to endothelial cells is an early event in atherosclerotic plaque formation 33 , and isoDGR formation has already been shown to promote leukocyte binding to endothelial cells during cancer development 34 . However, it remains unknown whether isoDGR motifs also contribute to the pathogenesis of human atherosclerosis. In a recent proteomic analysis of human carotid atherosclerotic plaques, we detected extensive deamidation of NGR motifs in several ECM component proteins including fibronectin (FN) and tenascin C (TNC) [35] [36] [37] [38] , which have been strongly implicated in the pathophysiology of atherosclerosis and CVD [39] [40] [41] [42] [43] [44] . We therefore hypothesized that deamidation of FN and TNC generates gain-of-function isoDGR motifs that mediate integrin binding and promote leukocyte recruitment to atherosclerotic plaque proteins. To test this hypothesis, we assessed the ECM adhesion capacity of mononuclear cells that express integrin α v β 3 . Using this approach, we demonstrate that as little as 5-8% deamidation of NGR motifs in FN and TNC can significantly enhance mononuclear cell adhesion to key ECM components. Our data indicate that ECM protein deamidation may promote plaque formation via recruitment of circulating monocytes due to gain-of-function structural changes that increase binding to integrin α v β 3 .
Results
Atherosclerotic plaque-derived ECM proteins exhibit highly deamidated NGR motifs. In a previous mass spectrometry-based proteomic analysis of carotid plaque tissues, we identified >4,500 individual proteins and multiple novel pathways implicated in the development and progression of human atherosclerosis 38 . Sample processing for this earlier investigation was conducted in ammonium acetate buffer (pH 6.5) which permits in-depth analysis of protein deamidation 45 , so in the current study we interrogated these data to identify that many key ECM proteins including FN and TNC displayed extensive deamidation at NGR motifs (Table 1) . Most of the isoDGR-containing proteins identified displayed ~50% deamidation of NGR sites, and selected proteins including EMILIN1 and LOXL1 exhibited 100% deamidation of specific residues (N219 in EMILIN1 and N365 in LOXL1). Given that EMILIN1 and LOXL1 are involved in the regulation of vascular assembly and flexibility [46] [47] [48] [49] [50] [51] , it is possible that deamidation leading to functional impairment of these proteins could promote atherosclerosis in human patients.
We and others have previously reported the optimal protein database search parameters for robust identification of deamidation sites. By applying a 5ppm precursor ion tolerance and # 13 C of 2 in Mascot searches, we prevented the C13 peaks of native peptides being misassigned as the monoisotopic peaks of the deamidated peptides 45, 52 . Numerous earlier studies have indicated that atherosclerotic disease is strongly associated with plaque accumulation of FN (which features NGR motifs at residues 263, 367, 501 and 1432) [42] [43] [44] , as well as TNC (which includes NGR motifs at residues 2031 and 2118) 40, [53] [54] [55] . In the current report, our use of optimized search parameters revealed that both FN and TNC exhibit significant deamidation of their respective NGR motifs. The deamidated and native peptides were identified with high confidence by Mascot protein database searches with extensive y-ions fragments (Figs 1 and S1 and Supplementary Data 1). The Mascot-identified peptides are included in Supplementary Data 2. Using a spectral counting quantitation method 56 , we observed that FN peptide GNLLQCICTGNGRGEW displayed 55.7% deamidation of the NGR motif, whereas TNC peptides NGRENFYQNWK and VEGYSGTAGDSMAYHNGR exhibited 50% and 18% deamidation respectively at the NGR domain (Table 1) , which was significantly higher than the 6.4% basal deamidation level detected across the rest of the proteome. These data suggest that ECM proteins FN and TNC display elevated levels of deamidation in atherosclerotic plaques and that these post-translational modifications may promote disease pathogenesis.
Monocyte adhesion to fibronectin and tenascin C is increased by NGR deamidation. We next hypothesized that isoDGR modifications in ECM proteins promote integrin-mediated mononuclear cell adhesion and recruitment into atherosclerotic plaques, leading to arterial dysfunction and disease progression. To test this possibility, we assessed the ability of integrin α v β 3 -expressing pre-monocytic cells to adhere to ECM proteins FN and TNC that had been coated onto plastic overnight in the presence or absence of 50 mM tetraethyl ammonium bicarbonate (TEAB) buffer (pH 8.5) to induce asparagine deamidation. We first assessed the extent of protein deamidation induced by TEAB treatment by extracting plate-bound FN and TNC for LC-MS/MS analysis, which revealed extensive FN deamidation at residue 263 in the sequence GNLLQCICTGNGRGEWK and marked TNC deamidation at residue 2118 in the sequence VEGYSGTAGDSMAYHNGR. The percentage of deamidation at each targeted NGR motif was determined by integrating the area of the extracted ion chromatogram (XIC) with the calculated precursor masses of the native and deamidated peptides (+/− 5 ppm mass range). Using this approach, we determined that overall levels of protein deamidation in TEAB-treated plates were ~8% for FN and ~5.3% for TNC, whereas the PBS-treated control plates exhibited <0.5% deamidation of either protein (Fig. 2) . We therefore proceeded to test the capacity of these different ECM substrates to bind U937 pre-monocytic cells that had been stimulated with 50 ng TPA (12-O-tetradecanoyl Phorbol-13-acetate) 57 to induce differentiation and upregulation of integrin α v β 3 . Western blot analyses indicated that β 3 integrin expression was increased after 3 h and reached a stable maximum within 12-24 h of TPA treatment, consistent with differentiation of U937 cells towards a macrophage phenotype (Fig. S2a,b) . We therefore elected to stimulate U937 Scientific RepoRts | 7: 5765 | DOI:10.1038/s41598-017-06202-2 cells with 50 ng TPA for 24 h and then incubate for 48 h in fresh RPMI-1640 medium supplemented with 10% FBS prior to use in the cell adhesion assays 58 . Analysis by microscopy revealed that the number of adherent U937 cells counted within a fixed area during the 60 min assay period was increased ~2-fold in the presence of deamidated FN (Fig. 3b) and ~2.5-fold with deamidated TNC (Fig. 4b ) compared with unmodified protein controls. Preferential monocyte-macrophage binding to deamidated FN was observed within just 15 min and continued to increase over the entire assay period (Fig. 3b) , while increased cell adhesion to deamidated TNC was evident after 30-60 min incubation (Fig. 4a,b) . Similar data were obtained when using these same assays to determine the binding capacity of primary human CD14+ blood monocytes, which also displayed preferential adhesion to deamidated FN (~1.3-fold) and deamidated TNC (~2-fold) (Fig. 5b) .
Integrin α v β 3 mediates monocyte-macrophage binding to deamidated ECM Proteins. Our observation that monocyte-macrophages expressing α v β 3 preferentially adhere to deamidated FN and TNC suggested that isoDGR modification of these proteins can enhance integrin binding. We therefore assessed whether the preferential binding of U937 cells to deamidated ECM proteins was attenuated in the presence of the α v -selective antagonist cilengitide 59 and results were further confirmed by blocking of integrins α v and β 3 using monoclonal antibodies. Primed U937 cells were incubated with or without 5 µg cilengitide overnight and then assessed for ability to bind to unmodified or deamidated ECM proteins via counting of adherent cells (Figs 3a,b and 4a,b). Consistent with our previous findings, U937 cell binding to deamidated FN was increased >2-fold relative to the unmodified control protein, whereas cilengitide treatment impaired cell binding to both the unmodified and deamidated proteins (Fig. 3a,b) . Cilengitide-mediated blocking of integrin α v conferred a ~3-fold reduction in U937 cell binding to both native and deamidated FN compare to their native control, although the inhibitory effect declined with increasing assay duration (Fig. 3a,b) . Cilengitide also induced a ~4-fold reduction in cell adhesion to native and deamidated TNC protein respect to the native control over the 60 min assay period (Fig. 4a,b) . Inhibition of α v and β 3 using monoclonal blocking antibodies replicated the effect of cilengitide (Figs 3a,b and 4a,b). A maximum of 2.88-fold and 2.86-fold reduction in cell adhesion to both native and deamidated FN was achieved by respective α v and β 3 monoclonal blocking antibodies while the vales were 3.6-fold and 3.7-fold for TNC protein (Figs 3a,b and 4a,b). Together, these data reveal that deamidation of NGR motifs in ECM proteins FN and TNC enhances monocyte-macrophage adhesion mediated by α v β 3 integrin and likely promotes leukocyte recruitment to human atherosclerotic plaques.
Discussion
The current report provides evidence of a critical role for isoDGR motifs in mediating leukocyte adhesion to the ECM via interactions with integrin α v β 3 and indicates that protein deamidation may promote atherosclerosis and unmodified form (GNLLQCICTGNGRGEW) as annotated by Mascot database search software (a). The deamidation site was identified with high confidence as being located between sequences (y1, y2, y4, y6) and (y7-y14). Each of the fragmented y-ions containing a deamidation site (y7-y14) displayed a characteristic mass increase of 0.984 Da compared with the unmodified peptide 45, 52 .
by enhancing monocyte-macrophage recruitment to developing plaques. Integrins are heterodimeric transmembrane molecules that bind to a conserved RGD sequence present in various host peptides 60 , but it has long been recognised that alternative motifs may also be capable of mediating integrin binding. In 1995, the peptide NGRAHA was identified by Koivunen and colleagues as a low-affinity homolog of the RGD ligand for α v β 3 integrin 61 , but it was not until 2006 that Curnis et al. reported that the NGR domain of fibronectin can undergo asparagine deamidation to form isoaspartic acid and increase integrin binding 6 . Our data now indicate that deamidation of ECM components can also induce gain-of-function structural changes that increase monocyte-macrophage binding to atherosclerotic plaque proteins.
During early-phase vascular injury, circulating monocytes migrate to the dysfunctional endothelial lining where they differentiate into macrophages (MФ) and produce pro-inflammatory cytokines and chemokines that recruit additional monocytes 33 . Having populated the endothelial lining, MФ then engulf oxidised LDL deposits in the lamina and develop into foam cells which are strongly associated with disease progression 33, 62 . Our data now suggest that deamidation-prone ECM proteins containing NGR motifs are likely to undergo gain-of-function modifications under stress conditions such as local inflammation during vascular injury 63 . We report for the first time that asparagine deamidation of the extracellular matrix proteins FN and TNC in particular can enhance monocyte adhesion via isoDGR interactions with integrin α v β 3 . Our initial proteomic analysis of human carotid atherosclerotic plaque tissues demonstrated that both FN and TNC proteins exhibit extensive NGR deamidation in vivo, and we further showed that these modifications confer a significant increase in monocyte-macrophage adhesion to ECM in vitro. Indeed, our observation that monocyte binding to the ECM was increased up to ~3.5-fold following induction of isoDGR motifs suggests that this mechanism could exert a major influence on the rate of plaque formation in human patients.
FN is a ubiquitous and highly abundant protein in human plasma and ECM. Initially secreted as a soluble disulphide-bonded dimer, FN is subsequently assembled into an insoluble multimeric protein in the ECM and provides structural support via interactions with collagens and fibrin. FN has also been shown to mediate cell surface receptor interactions with the ECM via activation of intracellular cytoskeletal rearrangements and signalling pathways. Consequently, FN is particularly abundant in tissues that are undergoing active regeneration in response to injury and has been strongly implicated in the pathology of atherosclerosis leading to cardiovascular disease [42] [43] [44] . Increased expression of FN in the injured vascular wall regulates smooth muscle cell transformation from a contractile phenotype to a synthesizing/proliferative phenotype that may contribute to intimal thickening. In atherosclerotic lesions there is a marked increase in FN co-localization with collagen type III, which is an archetypal feature of the tissue repair process during wound healing, whereas inhibition of FN expression using angiotensin II receptor antagonists is associated with a decrease in intimal thickening. These data suggest that drug targeting of FN structure-function changes may yield therapeutic benefit in human CVD patients.
TNC is highly expressed during embryogenesis but is almost absent in postnatal life and lacking in healthy arterial tissues 53 . However, TNC can be detected in tissues undergoing active remodelling and is up-regulated in atherosclerotic plaques where the protein reportedly contributes to smooth muscle cell migration and proliferation 54 . Sharifi and co-workers used immunohistochemical staining and in situ hybridization to demonstrate that TNC co-localizes with macrophages in human coronary atherosclerotic plaques that feature an organized lipid core or areas of rupture 40 , thus indicating that TNC expression and distribution correlate with inflammation. In a separate study, analysis of single nucleotide polymorphisms in human aortic tissues revealed that TNC genetic variants are strongly associated with atherosclerosis and coronary artery disease 55 . Taken together, these data demonstrate that FN and TNC are closely linked with the pathology of atherosclerosis and may represent promising targets for clinical interventions.
Intriguingly, we observed that the extent of TEAB-induced deamidation in fibronectin and tenascin C was <10% higher than the levels of spontaneous NGR deamidation observed in the untreated control. These data are consistent with previous reports that spontaneous NGR deamidation of ECM proteins is highly dependent on flanking residues, secondary/tertiary structure, and overall three-dimensional conformation 64 , which can be influenced by microenvironmental conditions including pH, temperature, and ionic strength 65 . Our data now reveal that these factors are also likely to exert a major influence on human atherosclerotic plaque progression to CVD via effects on monocyte-macrophage recruitment to the affected tissues. Pre-treatment of monocytic cells with the cyclic RGD-based pentapeptide cilengitide blocks α v β 3 integrin binding sites and reduced adhesion to NGR-deamidated fibronectin and tenascin C by 3-4-fold. The specific blocking of α v and β 3 integrin by monoclonal blocking antibodies reproduce the effect as achieved by RGD-motif specific blocking by cilengitide confirms the NGR-deamidation mediated integrin binding which mimic the RGD-specific integrin binding. Since protein deamidation is a spontaneous reaction the quantity of modified protein present in affected tissues progressively increases with time [9] [10] [11] . We used human carotid plaque tissues from elderly donors, hence the samples contained significant amounts of deamidated FN and TNC (acquired over the course of natural ageing). Deamidation of freshly prepared proteins by short-term chemical treatment in vitro was predictably lower than can be generated in vivo, but still conferred a significant increase in leukocyte adhesion to ECM. It is therefore possible that deamidation of FN and TNC in human tissues in vivo leads to even greater enhancement of leukocyte recruitment to carotid plaques than was observed in our assays. Collectively, these findings indicate that deamidation of the NGR domain confers gain-of-function changes in ECM proteins that increase leukocyte binding mediated by α v β 3 . Therapeutic targeting of this novel mechanism may represent an effective approach to inhibiting plaque development and delaying/preventing progression to CVD in human patients.
Conclusion
In this study, we performed proteomic profiling of human carotid atherosclerotic plaque samples and identified that numerous extracellular matrix (ECM) proteins display isoDGR motifs with potential 'gain-of-function' properties. IsoDGR is generated by deamidation of the NGR domain in select ECM proteins and mimics the functions of the integrin α v β 3 -binding RGD motif. Accordingly, monocyte-macrophage adhesion to ECM proteins was Figure 5 . Microscopy images of primary human monocyte adhesion to culture plates coated with fibronectin or tenascin C native proteins (PBS-only treated controls) or the deamidated forms of these ECM components (50 mM TEAB treated). Isolated monocytes were labelled with CFSE dye and the images captured using green fluorescent filter. Scale bar indicates 20 µm. Statistics were calculated from 4 experimental replicates.
Scientific RepoRts | 7: 5765 | DOI:10.1038/s41598-017-06202-2 significantly enhanced upon NGR deamidation of the atherosclerosis-associated matrix components fibronectin and tenascin C via a mechanism that required integrin α v β 3 . In conclusion, deamidation of asparagine residues in the NGR motif of atherosclerotic plaque proteins likely contributes to disease progression via recruitment of circulating monocytes that adhere to the modified ECM via integrin α v β 3 .
Materials and Methods
Antibodies and reagents. All reagents and chemicals used in this study were purchased from Sigma (St. Louis, USA) unless otherwise specified. For cell culture, RPMI-1640 medium was purchased from PAA Laboratories GmbH (Austria). Tenascin C protein (Cat. No. CC065) was obtained from EMD Millipore (Billerica, Massachusetts, USA). Cilengitide was purchased from Selleckchem (Houston, USA). Rabbit anti-human integrin α v and β 3 were from Cell Signaling Technologies, Inc. (Danvers, MA, USA) . HRP goat anti-rabbit IgG secondary antibody was from Zymed (San Francisco, California, USA). Sequencing-grade trypsin was from Promega (Madison, MI, USA). Human Pan Monocyte Isolation Kits were purchase from Miltenyi Biotec GmbH (Germany) and 5-Carboxyfluorescein N-Succinimidyl ester (CFSE) fluorescent dye was purchase from Cayman Chemical (Michigan, USA).
Proteomic profiling of human carotid atherosclerotic plaques. LC-MS/MS-based proteomic profiling of human atherosclerotic plaque tissues was performed as previously described 45 . Briefly, atherosclerotic plaque samples were obtained from n = 38 patients who underwent carotid endarterectomy at University Medical Center Utrecht (Netherlands) between 2002 and 2006 66 . Patients were aged 56-83 and included 32 males and 6 females. The clinical study has been approved by the Institutional Review board of the hospital and written informed consent was obtained from all patients. The experimental protocols were approved by the relevant ethical boards and were conducted in accordance with NTU guidelines. Blood clots were removed from the plaque samples, followed by extensive washing with PBS to remove any soluble materials prior to use in our analyses. Each of the 38 atherosclerotic plaque samples was transferred into lysis buffer (8 M Urea, 50 mM ammonium acetate, pH 6) containing protease inhibitors and then homogenized using a Bullet Blender ® (Next Advance, Inc., NY), before pooling and subjecting these to trypsin digestion. The tryptic peptides derived from the atherosclerotic plaque samples were prepared as previously described, with minor modifications 45 . Peptides generated from approximately 1 mg of proteins were fractionated using ERLIC on a HPLC system and then combined into 20 separate fractions 67 . Peptides from each fraction were separated and analyzed in triplicate on a Dionex Ultimate 3000 RSLCnano system coupled to a Q Exactive instrument (Thermo Scientific, San Jose, USA). The raw data are available for download from PeptideAtlas using the dataset identifier PASS00406 (http://www.peptideatlas.org/ PASS/PASS00406). Raw data were converted to Mascot generic file (mgf) format using Proteome Discoverer v1.4 (Thermo Scientific, San Jose, USA) with deisotope in MS/MS. The mgf files were searched against the Uniprot human proteome database in Mascot using the following parameters; fixed modification: Carbamidomethyl, Cell culture. Pro-monocytic U937 cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 1 mM sodium pyruvate. Cells were differentiated by stimulation with 50 ng/ml Phorbol 12-myristate 13-acetate (PMA) (Sigma, St. Louis, MO, USA) for 24 h followed by a further 48 h incubation in fresh culture medium.
Cell adhesion assay. ECM proteins were coated onto 96-well plates (2 µg protein in 50 µl PBS, pH 6.8) via overnight incubation at 37 °C. Non-adhered ECM proteins were then removed and the wells washed twice with PBS. Deamidation of ECM proteins was induced by addition of 50 mM TEAB buffer (pH 8.5) and overnight incubation at 37 °C. All wells were then washed twice with PBS to remove residual TEAB prior to addition of differentiated U937 cells (1 × 10 4 cells per well) and incubation at 37 °C for the indicated times. In inhibition experiments, U937 cells were pre-treated with 5 µg cilengitide overnight (1 × 10 4 cells per condition) prior to use in the adhesion assays. Alternatively, blocking of α v and β 3 was achieved by incubating U937 cells with the corresponding anti-integrin monoclonal antibodies (1:500 dilution) in 10% FBS-supplemented DMEM at 37 °C for 1 h immediately prior to use in adhesion assays. After incubation, non-adherent cells were removed from the wells by washing twice with PBS. Adherent cells were fixed by addition of 95% ethanol for 15 min at RT. The fixed cells were then stained with crystal violet for 20 min followed by extensive washing with PBS to remove excess dye. Images of the adherent cells were captured using a Nikon EU 2000 inverted microscope. Quantification was performed by cell counting in experimental triplets and the statistical significance was calculated by using nonparametric one-way ANOVA with multiple comparisons test.
Primary Monocyte Adhesion Assay. Blood samples were obtained after written informed consent from two healthy volunteers recruited via NTU health clinic (Singapore). Experimental protocols were approved by the ethical boards and were conducted in accordance with NTU guidelines. Human peripheral blood mononuclear cells (PBMCs) were isolated from each fresh 15 ml blood sample by density gradient centrifugation over Histopaque-1077 at 400 × g for 20 min. Finally, the human primary monocytes were isolated from PBMCs using monocyte isolation kits according to the manufacturer's protocol. Isolated monocytes were suspended in PBS and labelled with 10 µM CFSE for 10 min at 37 °C prior to use in the adhesion assays (~3 × 10 4 cells per well). Images of adherent cells were captured in the green fluorescence channel of a Nikon ECLIPSE Ti-S inverted microscope coupled with a Nikon DS-Ri2 camera. Quantification was performed by cell counting in 4 experimental replicates and nonparametric one-way ANOVA was used for a comparison between groups.
Western blotting. U937 cells were stimulated with PMA for the indicated times and cell lysate was collected for assessment of β 3 integrin expression levels. Briefly, cells were lysed in RIPA buffer containing a cocktail of EDTA-free protease inhibitors (Roche, Mannheim, Germany) and phosphatase inhibitors (Roche, Mannheim, Germany). Lysates were clarified by centrifugation (16,000 × g, 30 min) and subjected to Western blotting using an anti-integrin β 3 antibody (1:1000 dilution). Protein-antibody conjugates were visualized using a chemiluminescence detection kit according to the manufacturer's protocol (Thermo Scientific).
ECM protein extraction. ECM proteins were extracted from coated 96-well plates for LC-MS/MS analysis to determine the extent of deamidation. TEAB-treated (deamidated) and PBS-treated (non-deamidated) plates were incubated with 8 M urea and 50 mM ammonium acetate (pH 6.5) on a rotatory shaker for 2 h at 37 °C. Proteins extracted into the urea buffer were then collected in a microcentrifuge tube and precipitated in chilled acetone by incubation at −20 °C overnight. Precipitated proteins were finally subjected to LC-MS/MS analysis of deamidation.
LC-MS/MS analysis of ECM protein deamidation.
Extracted ECM protein samples were reduced, alkylated, and diluted with ammonium acetate to achieve 1 M urea prior to trypsin digestion overnight at 37 °C. The digested protein samples were desalted and dried in a vacuum concentrator. Tryptic peptides were then separated and analysed on a Dionex Ultimate 3000 RSLC-nano system coupled to a LTQ-FT Ultra (Thermo Electron, Bremen, Germany) using a C18 nano-HPLC column with a standard LC-MS/MS gradient. Peptide ions were analysed on LTQ-FT with an ADVANCE ™ CaptiveSpray ™ Source (Michrom BioResources, USA). Spectra were acquired with XCalibur (version 2.0 SR2). MS/MS spectra were extracted from raw data and converted into mgf files in Proteome Discoverer 1.4 before searching these against the human database in Mascot software (parameters used were; fixed modification: Carbamidomethyl, variable modification: Deamidation (NQ), Oxidation (M); MS/MS tolerance 5.1 ppm, peptide mass tolerance: 0.8 Da, No. of missed cleavage: 2). The Mascot-annotated MS/ MS spectra of the targeted deamidated and non-deamidated peptides were confirmed by manual inspection of the search results. The percentage of deamidation at each targeted NGR motif was determined by the area of the extracted ion chromatogram integrated with +/− 5 ppm mass range of the calculated precursor masses of the native and deamidated peptides.
